This reduction in the number of groups (from four subtypes to two classes) suggests that the genes that PAM50 uses to subdivide the more proliferative tumors into luminal B, Her2-enriched and basal-like (ESR1- and ERBB2-associated genes) [82] do not serve that same purpose in a pan-cancer context. This evidence concerns the gene ERBB2 and cancer.